Markets

Foamix Starts Patient Enrollment in Phase II Study on FMX103

A generic image of a person holding dollar bills.
Credit: Shutterstock photo

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized.

Earlier this week, Foamix Pharmaceuticals Ltd.FOMX announced the initiation of patient enrollment in a phase II study on FMX103 for the treatment of papulopustular rosacea.

The double-blind, randomized placebo-controlled study will evaluate patients with moderate-to-severe papulopustular rosacea. The company expects to file a New Drug Application (NDA) with the FDA under the agency's 505(b)(2) regulatory pathway.

According to information provided by the company, more than 16 million people in the U.S. are affected by papulopustular rosacea.

Meanwhile, the company continues to progress on its pipeline. The company's lead pipeline candidate FMX101, which has the same active ingredient as FMX103, minocycline, is being developed for the treatment of patients with acne. The company expects to initiate phase III studies in early 2016 and complete them in 2017.

In addition, the company is evaluating another candidate FDX104 in a phase II study for treatment of chemotherapy-induced rash in cancer patients taking epidermal growth factor receptor inhibitors such as Erbitux and Vectibix. Top-line results are expected in the fourth quarter of 2015.

Foamix carries a Zacks Rank #4 (Sell). Some better-ranked stock in the health care sector includes AstraZeneca PLC AZN , Amgen Inc. AMGN and Anika Therapeutics Inc. ANIK , each sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

FOAMIX PHARMA (FOMX): Free Stock Analysis Report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

AMGEN INC (AMGN): Free Stock Analysis Report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ANIK AZN AMGN

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More